Selected research
Industry Research
GalNAc-based Drug Industry Research Report 2026
Market perspective
The global GalNAc-based Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the GalNAc-based Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the GalNAc-based Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the GalNAc-based Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of GalNAc-based Drug include Suzhou Ribo Life Science Co., Ltd, Sirnaomics, Novartis, Novo Nordisk (Dicerna), Hitgen (Leaderna Therapeutics Ltd.), Silence Therapeutics, Ionis, Arrowhead and Arbutus and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global GalNAc-based Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to GalNAc-based Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
GalNAc-based Drug Market by Company
Suzhou Ribo Life Science Co., Ltd
Sirnaomics
Novartis
Novo Nordisk (Dicerna)
Hitgen (Leaderna Therapeutics Ltd.)
Silence Therapeutics
Ionis
Arrowhead
Arbutus
Alnylam Pharmaceuticals
GalNAc-based Drug Segment by Type
siRNA Based
ASO Based
GalNAc-based Drug Segment by Application
Metabolic Diseases
Neurological Diseases
Cardiovascular Diseases
Other
GalNAc-based Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GalNAc-based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GalNAc-based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GalNAc-based Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of GalNAc-based Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- siRNA Based
- ASO Based
Applications
- Metabolic Diseases
- Neurological Diseases
- Cardiovascular Diseases
- Other
Companies covered
- Suzhou Ribo Life Science Co., Ltd
- Sirnaomics
- Novartis
- Novo Nordisk (Dicerna)
- Hitgen (Leaderna Therapeutics Ltd.)
- Silence Therapeutics
- Ionis
- Arrowhead
- Arbutus
- Alnylam Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 GalNAc-based Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 siRNA Based
- 2.2.3 ASO Based
- 2.3 GalNAc-based Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Metabolic Diseases
- 2.3.3 Neurological Diseases
- 2.3.4 Cardiovascular Diseases
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 GalNAc-based Drug Breakdown Data by Type
- 3.1 Global GalNAc-based Drug Historic Market Size by Type (2021-2026)
- 3.2 Global GalNAc-based Drug Forecasted Market Size by Type (2027-2032)
4 GalNAc-based Drug Breakdown Data by Application
- 4.1 Global GalNAc-based Drug Historic Market Size by Application (2021-2026)
- 4.2 Global GalNAc-based Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global GalNAc-based Drug Market Perspective (2021-2032)
- 5.2 Global GalNAc-based Drug Growth Trends by Region
- 5.2.1 Global GalNAc-based Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 GalNAc-based Drug Historic Market Size by Region (2021-2026)
- 5.2.3 GalNAc-based Drug Forecasted Market Size by Region (2027-2032)
- 5.3 GalNAc-based Drug Market Dynamics
- 5.3.1 GalNAc-based Drug Industry Trends
- 5.3.2 GalNAc-based Drug Market Drivers
- 5.3.3 GalNAc-based Drug Market Challenges
- 5.3.4 GalNAc-based Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top GalNAc-based Drug Players by Revenue
- 6.1.1 Global Top GalNAc-based Drug Players by Revenue (2021-2026)
- 6.1.2 Global GalNAc-based Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global GalNAc-based Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of GalNAc-based Drug Head Office and Area Served
- 6.4 Global GalNAc-based Drug Players, Product Type & Application
- 6.5 Global GalNAc-based Drug Manufacturers Established Date
- 6.6 Global GalNAc-based Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America GalNAc-based Drug Market Size (2021-2032)
- 7.2 North America GalNAc-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America GalNAc-based Drug Market Size by Country (2021-2026)
- 7.4 North America GalNAc-based Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe GalNAc-based Drug Market Size (2021-2032)
- 8.2 Europe GalNAc-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe GalNAc-based Drug Market Size by Country (2021-2026)
- 8.4 Europe GalNAc-based Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific GalNAc-based Drug Market Size (2021-2032)
- 9.2 Asia-Pacific GalNAc-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific GalNAc-based Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific GalNAc-based Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America GalNAc-based Drug Market Size (2021-2032)
- 10.2 South America GalNAc-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America GalNAc-based Drug Market Size by Country (2021-2026)
- 10.4 South America GalNAc-based Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa GalNAc-based Drug Market Size (2021-2032)
- 11.2 Middle East & Africa GalNAc-based Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa GalNAc-based Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa GalNAc-based Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Suzhou Ribo Life Science Co., Ltd
- 12.1.1 Suzhou Ribo Life Science Co., Ltd Company Information
- 12.1.2 Suzhou Ribo Life Science Co., Ltd Business Overview
- 12.1.3 Suzhou Ribo Life Science Co., Ltd Revenue in GalNAc-based Drug Business (2021-2026)
- 12.1.4 Suzhou Ribo Life Science Co., Ltd GalNAc-based Drug Product Portfolio
- 12.1.5 Suzhou Ribo Life Science Co., Ltd Recent Developments
- 12.2 Sirnaomics
- 12.2.1 Sirnaomics Company Information
- 12.2.2 Sirnaomics Business Overview
- 12.2.3 Sirnaomics Revenue in GalNAc-based Drug Business (2021-2026)
- 12.2.4 Sirnaomics GalNAc-based Drug Product Portfolio
- 12.2.5 Sirnaomics Recent Developments
- 12.3 Novartis
- 12.3.1 Novartis Company Information
- 12.3.2 Novartis Business Overview
- 12.3.3 Novartis Revenue in GalNAc-based Drug Business (2021-2026)
- 12.3.4 Novartis GalNAc-based Drug Product Portfolio
- 12.3.5 Novartis Recent Developments
- 12.4 Novo Nordisk (Dicerna)
- 12.4.1 Novo Nordisk (Dicerna) Company Information
- 12.4.2 Novo Nordisk (Dicerna) Business Overview
- 12.4.3 Novo Nordisk (Dicerna) Revenue in GalNAc-based Drug Business (2021-2026)
- 12.4.4 Novo Nordisk (Dicerna) GalNAc-based Drug Product Portfolio
- 12.4.5 Novo Nordisk (Dicerna) Recent Developments
- 12.5 Hitgen (Leaderna Therapeutics Ltd.)
- 12.5.1 Hitgen (Leaderna Therapeutics Ltd.) Company Information
- 12.5.2 Hitgen (Leaderna Therapeutics Ltd.) Business Overview
- 12.5.3 Hitgen (Leaderna Therapeutics Ltd.) Revenue in GalNAc-based Drug Business (2021-2026)
- 12.5.4 Hitgen (Leaderna Therapeutics Ltd.) GalNAc-based Drug Product Portfolio
- 12.5.5 Hitgen (Leaderna Therapeutics Ltd.) Recent Developments
- 12.6 Silence Therapeutics
- 12.6.1 Silence Therapeutics Company Information
- 12.6.2 Silence Therapeutics Business Overview
- 12.6.3 Silence Therapeutics Revenue in GalNAc-based Drug Business (2021-2026)
- 12.6.4 Silence Therapeutics GalNAc-based Drug Product Portfolio
- 12.6.5 Silence Therapeutics Recent Developments
- 12.7 Ionis
- 12.7.1 Ionis Company Information
- 12.7.2 Ionis Business Overview
- 12.7.3 Ionis Revenue in GalNAc-based Drug Business (2021-2026)
- 12.7.4 Ionis GalNAc-based Drug Product Portfolio
- 12.7.5 Ionis Recent Developments
- 12.8 Arrowhead
- 12.8.1 Arrowhead Company Information
- 12.8.2 Arrowhead Business Overview
- 12.8.3 Arrowhead Revenue in GalNAc-based Drug Business (2021-2026)
- 12.8.4 Arrowhead GalNAc-based Drug Product Portfolio
- 12.8.5 Arrowhead Recent Developments
- 12.9 Arbutus
- 12.9.1 Arbutus Company Information
- 12.9.2 Arbutus Business Overview
- 12.9.3 Arbutus Revenue in GalNAc-based Drug Business (2021-2026)
- 12.9.4 Arbutus GalNAc-based Drug Product Portfolio
- 12.9.5 Arbutus Recent Developments
- 12.10 Alnylam Pharmaceuticals
- 12.10.1 Alnylam Pharmaceuticals Company Information
- 12.10.2 Alnylam Pharmaceuticals Business Overview
- 12.10.3 Alnylam Pharmaceuticals Revenue in GalNAc-based Drug Business (2021-2026)
- 12.10.4 Alnylam Pharmaceuticals GalNAc-based Drug Product Portfolio
- 12.10.5 Alnylam Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst